{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:22:51Z","timestamp":1792581771104,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To demonstrate the treatment efficacy of intravitreal dexamethasone (DEX) implant in chronic recurrent\/persistent central serous chorioretinopathy (CSC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Prospective, non-randomized, open-label study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this study, subjects with chronic CSC without signs of choroidal neovascularization (CNV) received intravitreal DEX implant therapy. The primary outcome measure was the change in visual acuity. Changes in central macular thickness (CMT) and change in subfoveal choroidal thickness (SFCT) on optical coherence tomography (OCT), incidence of recurrent fluid, and safety of DEX implant were secondary outcome measures. Subjects were followed up for a minimum of 3 months after DEX implantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In total, 20 eyes of 20 subjects (mean age: 47 \u00b1 9 years) with a median disease duration of 23.5 months were enrolled. With a single injection of DEX implant, a reduction in CMT was noted in 90% of eyes. Complete resolution of subretinal and intraretinal fluid was noted in 55% of eyes within 3 months of injection. A significant improvement in vision (mean Log MAR visual acuity: 0.66 \u00b1 0.49 vs. 0.54 \u00b1 0.45;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.020), mean CMT (338 \u00b1 110 microns to 238 \u00b1 73 microns;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and SFCT (514 \u00b1 95 microns to 445 \u00b1 111 microns;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) was noted over 3 months. Recurrent fluid was noted in 50% of eyes after a mean follow-up duration of 7 \u00b1 4 months. Elevated intraocular pressure, managed by topical therapy, was noted in six eyes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The consistent improvement in visual acuity, fluid resolution, and reduction in choroidal thickness suggests a possible role for DEX implants in managing chronic CSC. A larger randomized trial is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_626_24","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T12:09:53Z","timestamp":1720699793000},"page":"S100-S106","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of dexamethasone implant in the management of chronic central serous chorioretinopathy without choroidal neovascularization"],"prefix":"10.4103","volume":"73","author":[{"given":"Umesh Chandra","family":"Behera","sequence":"first","affiliation":[{"name":"Retina Vitreous Service, Anant Bajaj Retina Institute, L V Prasad Eye Institute (Mithu Tulsi Chanrai Campus), Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand S","family":"Brar","sequence":"additional","affiliation":[{"name":"Retina Vitreous Service, Anant Bajaj Retina Institute, L V Prasad Eye Institute (Mithu Tulsi Chanrai Campus), Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Kelgaonkar","sequence":"additional","affiliation":[{"name":"Retina Vitreous Service, Anant Bajaj Retina Institute, L V Prasad Eye Institute (Mithu Tulsi Chanrai Campus), Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotiranjan","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Institute of Medical Sciences and SUM Hospital, Siksha \u2018O\u2019 Anusandhan Deemed to be University, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Retina Vitreous Service, Anant Bajaj Retina Institute, L V Prasad Eye Institute (Kallam Anji Reddy Campus), Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SriniVas R","family":"Sadda","sequence":"additional","affiliation":[{"name":"Doheny Image Reading Center, Doheny Eye Institute, University of California, Los Angeles, CA, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"R1-20260424","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.4103\/IJO.IJO_677_23","article-title":"Comparison of prevalent management options to treat acute central serous chorioretinopathy","volume":"71","author":"Pradhan","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R2-20260424","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4103\/IJO.IJO_2523_22","article-title":"Efficacy of intravitreal dexamethasone implant in chronic central serous chorioretinopathy. A pilot study","volume":"3","author":"Behera","year":"2023","journal-title":"Indian J Ophthalmol Case Rep"},{"key":"R3-20260424","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0002-9394(83)90265-9","article-title":"Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy","volume":"95","author":"Robertson","year":"1983","journal-title":"Am J Ophthalmol"},{"key":"R4-20260424","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ophtha.2013.11.040","article-title":"Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy","volume":"121","author":"Lim","year":"2014","journal-title":"Ophthalmology"},{"key":"R5-20260424","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/ICU.0b013e3283459826","article-title":"Review and update of central serous chorioretinopathy","volume":"22","author":"Ross","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"R6-20260424","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","article-title":"Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The PLACE Trial","volume":"125","author":"van Dijk","year":"2018","journal-title":"Ophthalmology"},{"key":"R7-20260424","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00006982-200306000-00002","article-title":"Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: A pilot study","volume":"23","author":"Yannuzzi","year":"2003","journal-title":"Retina"},{"key":"R8-20260424","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10384-008-0613-z","article-title":"Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy","volume":"53","author":"Lee","year":"2009","journal-title":"Jpn J Ophthalmol"},{"key":"R9-20260424","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00006982-200602000-00027","article-title":"Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy","volume":"26","author":"Colucciello","year":"2006","journal-title":"Retina"},{"key":"R10-20260424","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","article-title":"Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): A randomised, double-blind, placebo-controlled trial","volume":"395","author":"Lotery","year":"2020","journal-title":"Lancet"},{"key":"R11-20260424","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.oret.2017.05.013","article-title":"Dilatation of asymmetric vortex vein in central serous chorioretinopathy","volume":"2","author":"Hiroe","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R12-20260424","doi-asserted-by":"crossref","first-page":"100973","DOI":"10.1016\/j.preteyeres.2021.100973","article-title":"Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders","volume":"86","author":"Spaide","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"R13-20260424","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature07201","article-title":"Origin and physiological roles of inflammation","volume":"454","author":"Medzhitov","year":"2008","journal-title":"Nature"},{"key":"R14-20260424","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.preteyeres.2009.06.001","article-title":"Para-inflammation in the aging retina","volume":"28","author":"Xu","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"R15-20260424","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1111\/aos.14547","article-title":"Altered plasma cytokine levels in acute and chronic central serous chorioretinopathy","volume":"99","author":"Karska-Basta","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"R16-20260424","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1097\/IAE.0b013e31820a6a17","article-title":"Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy","volume":"31","author":"Shin","year":"2011","journal-title":"Retina"},{"key":"R17-20260424","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1111\/aos.13491","article-title":"Eplerenone for chronic central serous chorioretinopathy-A randomized controlled prospective study","volume":"95","author":"Schwartz","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"R18-20260424","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00417-019-04486-w","article-title":"Corticosteroids usage and central serous chorioretinopathy: A meta-analysis","volume":"258","author":"Ge","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R19-20260424","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ajo.2021.06.020","article-title":"Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): A randomized controlled trial","volume":"233","author":"van Rijssen","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R20-20260424","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","article-title":"The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980\u20132002","volume":"115","author":"Kitzmann","year":"2008","journal-title":"Ophthalmology"},{"key":"R21-20260424","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/aos.14269","article-title":"Hair cortisol concentrations in chronic central serous chorioretinopathy","volume":"98","author":"van Haalen","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"R22-20260424","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2017.06.008","article-title":"Central serous chorioretinopathy and glucocorticoids: An update on evidence for association","volume":"63","author":"Nicholson","year":"2018","journal-title":"Surv Ophthalmol"},{"key":"R23-20260424","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R24-20260424","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/jop.2014.0100","article-title":"Ocular pharmacokinetics of fluocinolone acetonide following Iluvien implantation in the vitreous humor of rabbits","volume":"31","author":"Kane","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"R25-20260424","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/IAE.0b013e31820a69ee","article-title":"Central serous chorioretinopathy after renal transplantation","volume":"31","author":"Lee","year":"2011","journal-title":"Retina"},{"key":"R26-20260424","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/S0161-6420(02)01117-X","article-title":"Corticosteroids and central serous chorioretinopathy","volume":"109","author":"Carvalho-Recchia","year":"2002","journal-title":"Ophthalmology"},{"key":"R27-20260424","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.4103\/IJO.IJO_1957_23","article-title":"Steroid challenge: Response to dexamethasone implant in persistent, simple central serous chorioretinopathy","volume":"3","author":"Behera","year":"2023","journal-title":"Indian J Ophthalmol Case Rep"},{"key":"R28-20260424","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1136\/bjophthalmol-2014-306417","article-title":"Changes in choroidal thickness after intravitreal dexamethasone implant injection in retinal vein occlusion","volume":"99","author":"Lee","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R29-20260424","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/IAE.0000000000002040","article-title":"Chronic central serous chorioretinopathy: Early and late morphological and functional changes after verteporfin photodynamic therapy","volume":"39","author":"Iacono","year":"2019","journal-title":"Retina"},{"key":"R30-20260424","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/aos.14775","article-title":"Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser","volume":"99","author":"van Rijssen","year":"2021","journal-title":"Acta Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_626_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:22:12Z","timestamp":1787836932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_626_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":30,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_626_24","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"2024-03-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}